- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Xolamid B
Brinzolamide + Brimonidine Tartrate
Description:
Brinzolamide is a carbonic anhydrase inhibitor and Brimonidine is an alpha 2 adrenergic receptor agonist.
Brinzolamide is a carbonic anhydrase inhibitor and Brimonidine is an alpha 2 adrenergic receptor agonist.
Indications:
Elevated intraocular pressure (IOP) in Open angle glaucoma or ocular hypertension.
Elevated intraocular pressure (IOP) in Open angle glaucoma or ocular hypertension.
Mode of Action:
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. It exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells, but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide is an inhibitor of carbonic anhydrase II with an in vitro IC50 of 3.2 nM and a Ki of 0.13n M against carbonic anhydrase-II. Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brimonidine is an alpha-2 adrenergic receptor agonist which reduces the production of aqueous humor from ciliary process. It has a peak ocular hypotensive effect occurring at two hours of post-dosing.
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. It exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells, but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide is an inhibitor of carbonic anhydrase II with an in vitro IC50 of 3.2 nM and a Ki of 0.13n M against carbonic anhydrase-II. Following topical ocular administration, brinzolamide inhibits aqueous humor formation and reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brimonidine is an alpha-2 adrenergic receptor agonist which reduces the production of aqueous humor from ciliary process. It has a peak ocular hypotensive effect occurring at two hours of post-dosing.
Different Dosages from Xolamid B
Other Brands From Same Therapeutic Class
